Join The Conversation! | https://trialsitenews.com/
Despite 95%+ full vaccination of adult populations in Australia, TrialSite has continued to report on surges in new COVID-19 cases, hospitalizations, and deaths. It is a disturbing situation that the mainstream press either completely ignores or summarily embraces as a context to promote further vaccination as the only answer. But is this an evidence-based approach to the problem? TrialSite reported that in the first 14 weeks of 2022, Australian fatalities due to COVID-19 were double that of 2020 and 2021 combined, despite near universal vaccination. By January 2022, TrialSite updated the global audience that in Australian states including New South Wales or “NSW,” the new increasingly Omicron-based cases were surging. TrialSite reviewed the latest data. Now, with a surge in B.4 and B.5 Omicron subvariants which more evade vaccine induced antibodies, a disturbing number of deaths are reported daily. What’s the level of protection the vaccines are affording to the population of NSW now that these subvariants circulate through this southeastern part of Australia?
Despite 95%+ full vaccination of adult populations in Australia, TrialSite has continued to report on surges in new COVID-19 cases, hospitalizations, and deaths. It is a disturbing situation that the mainstream press either completely ignores or summarily embraces as a context to promote further vaccination as the only answer. But is this an evidence-based approach to the problem? TrialSite reported that in the first 14 weeks of 2022, Australian fatalities due to COVID-19 were double that of 2020 and 2021 combined, despite near universal vaccination. By January 2022, TrialSite updated the global audience that in Australian states including New South Wales or “NSW,” the new increasingly Omicron-based cases were surging. TrialSite reviewed the latest data. Now, with a surge in B.4 and B.5 Omicron subvariants which more evade vaccine induced antibodies, a disturbing number of deaths are reported daily. What’s the level of protection the vaccines are affording to the population of NSW now that these subvariants circulate through this southeastern part of Australia?
